| combined BRAF-MEK inhibitors | KRAS gene alteration targeted therapy |
| trametinib plus dabrafenib | sotorasib |
| mNSCLC - L2 - adenocarcinoma cell | | |
| mNSCLC - L2 - all population 5 | | |
| mNSCLC - L2 - EGFR high | | |
| mNSCLC - L2 - EGFR mutant 1 | | |
| mNSCLC - L2 - EGFR wild type | | |
| mNSCLC - L2 - KRAS mutant | | |
| mNSCLC - L2 - KRAS wild type | | |
| mNSCLC - L2 - PDL1 negative 1 | | |
| mNSCLC - L2 - PDL1 positive 7 | | |
| non squamous cell - mNSCLC - L2 | | |
| non squamous - mNSCLC - L2 - all population 1 | | |
| non squamous - mNSCLC - L2 - EGFR mutant | | |
| non squamous - mNSCLC - L2 - PDL1 positive | | |
| non squamous - mNSCLC - L2 - wild type (WT) | | |
| squamous cell - mNSCLC - L2 | | |
| squamous - mNSCLC - L2 - all population 1 | | |
| squamous - mNSCLC - L2 - PDL1 positive | | |